These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 15613919)

  • 1. Effect of raloxifene on activated protein C (APC) resistance in postmenopausal women and on APC resistance and homocysteine levels in elderly men: two randomized placebo-controlled studies.
    Duschek EJ; Neele SJ; Thomassen MC; Rosing J; Netelenbos C
    Blood Coagul Fibrinolysis; 2004 Oct; 15(8):649-55. PubMed ID: 15613919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine levels in healthy postmenopausal women.
    Mijatovic V; Netelenbos C; van der Mooren MJ; de Valk-de Roo GW; Jakobs C; Kenemans P
    Fertil Steril; 1998 Dec; 70(6):1085-9. PubMed ID: 9848300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of estrogen, raloxifene, and hormone replacement therapy on serum C-reactive protein and homocysteine levels.
    Gol M; Akan P; Dogan E; Karas C; Saygili U; Posaci C
    Maturitas; 2006 Feb; 53(3):252-9. PubMed ID: 15990257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial.
    Høibraaten E; Mowinckel MC; de Ronde H; Bertina RM; Sandset PM
    Br J Haematol; 2001 Nov; 115(2):415-20. PubMed ID: 11703344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women.
    Post MS; Christella M; Thomassen LG; van der Mooren MJ; van Baal WM; Rosing J; Kenemans P; Stehouwer CD
    Arterioscler Thromb Vasc Biol; 2003 Jun; 23(6):1116-21. PubMed ID: 12730085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Raloxifene and hormone replacement therapy increase arachidonic acid and docosahexaenoic acid levels in postmenopausal women.
    Giltay EJ; Duschek EJ; Katan MB; Zock PL; Neele SJ; Netelenbos JC
    J Endocrinol; 2004 Sep; 182(3):399-408. PubMed ID: 15350182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system.
    Eilertsen AL; Liestøl S; Mowinckel MC; Hemker HC; Sandset PM
    Thromb Haemost; 2007 Jun; 97(6):938-43. PubMed ID: 17549295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 2-year, randomized, comparative, placebo-controlled study on the effects of raloxifene on lipoprotein(a) and homocysteine.
    Smolders RG; Vogelvang TE; Mijatovic V; van Baal WM; Neele SJ; Netelenbos JC; Kenemans P; van der Mooren MJ
    Maturitas; 2002 Feb; 41(2):105-14. PubMed ID: 11836041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of raloxifene and hormone replacement therapy on markers of serum atherogenicity in healthy postmenopausal women.
    Anderson PW; Cox DA; Sashegyi A; Paul S; Silfen SL; Walsh BW
    Maturitas; 2001 Jul; 39(1):71-7. PubMed ID: 11451623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial.
    Walsh BW; Paul S; Wild RA; Dean RA; Tracy RP; Cox DA; Anderson PW
    J Clin Endocrinol Metab; 2000 Jan; 85(1):214-8. PubMed ID: 10634389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neither long-term treatment with raloxifene nor hormone replacement therapy modulate cardiac function in healthy postmenopausal women: two randomized, placebo-controlled, 2-year studies.
    Vogelvang TE; Mijatovic V; Kamp O; Netelenbos JC; Neele SJ; Pines A; Kenemans P; van der Mooren MJ
    Am J Obstet Gynecol; 2002 Apr; 186(4):729-36. PubMed ID: 11967499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: A 2-year, placebo-controlled study.
    de Valk-de Roo GW; Stehouwer CD; Meijer P; Mijatovic V; Kluft C; Kenemans P; Cohen F; Watts S; Netelenbos C
    Arterioscler Thromb Vasc Biol; 1999 Dec; 19(12):2993-3000. PubMed ID: 10591680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uterine effects of raloxifene in comparison with continuous-combined hormone replacement therapy in postmenopausal women.
    Fugère P; Scheele WH; Shah A; Strack TR; Glant MD; Jolly E
    Am J Obstet Gynecol; 2000 Mar; 182(3):568-74. PubMed ID: 10739509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of urinary incontinence in postmenopausal women treated with raloxifene or estrogen.
    Goldstein SR; Johnson S; Watts NB; Ciaccia AV; Elmerick D; Muram D
    Menopause; 2005 Mar; 12(2):160-4. PubMed ID: 15772563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Raloxifene reduces procarboxypeptidase U, an antifibrinolytic marker. A 2-year randomized, placebo-controlled study in healthy early postmenopausal women.
    Vogelvang TE; Leurs JR; van der Mooren MJ; Mijatovic V; Hendriks DF; Neele SJ; Netelenbos JC; Kenemans P
    Menopause; 2004; 11(1):110-5. PubMed ID: 14716191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raloxifene lowers serum lipoprotein(A) in healthy postmenopausal women: a randomized, double-blind, placebo-controlled comparison with conjugated equine estrogens.
    Mijatovic V; van der Mooren MJ; Kenemans P; de Valk-de Roo GW; Netelenbos C
    Menopause; 1999; 6(2):134-7. PubMed ID: 10374220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women.
    Walsh BW; Kuller LH; Wild RA; Paul S; Farmer M; Lawrence JB; Shah AS; Anderson PW
    JAMA; 1998 May; 279(18):1445-51. PubMed ID: 9600478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of hormone therapy on plasma homocysteine levels: a randomized clinical trial.
    Tutuncu L; Ergur AR; Mungen E; Gun I; Ertekin A; Yergok YZ
    Menopause; 2005 Mar; 12(2):216-22. PubMed ID: 15772570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of oral conjugated equine estrogen combined with medroxyprogesterone acetate on plasma homocysteine levels in postmenopausal women.
    Hsu SC; Liu CM; Long CY; Yang CH; Lee JN; Tsai EM
    Fertil Steril; 2005 Oct; 84(4):1037-9. PubMed ID: 16213869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term urogenital effects of raloxifene, tamoxifen, and estrogen.
    Vardy MD; Lindsay R; Scotti RJ; Mikhail M; Richart RM; Nieves J; Zion M; Cosman F
    Am J Obstet Gynecol; 2003 Jul; 189(1):81-8. PubMed ID: 12861143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.